Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at BidaskClub

BidaskClub upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a strong-buy rating in a research note released on Wednesday morning, BidAskClub reports.

A number of other analysts have also commented on the company. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. They set an outperform rating and a $128.00 price target on the stock. Cowen reaffirmed a buy rating and issued a $120.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. UBS Group raised their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the stock a neutral rating in a research report on Wednesday, September 4th. Nomura set a $62.00 price target on Alnylam Pharmaceuticals and gave the company a sell rating in a research report on Tuesday, October 8th. Finally, BMO Capital Markets upped their price target on Alnylam Pharmaceuticals from $128.00 to $138.00 and gave the company an outperform rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $114.58.

Shares of ALNY opened at $123.76 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $125.72. The stock has a market capitalization of $13.80 billion, a price-to-earnings ratio of -16.35 and a beta of 2.46. The stock has a fifty day moving average of $98.68 and a 200-day moving average of $81.91.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.17) by $0.25. The business had revenue of $70.06 million during the quarter, compared to analysts’ expectations of $57.14 million. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. The business’s revenue for the quarter was up 3284.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.56) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -7.87 EPS for the current year.

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $91.71, for a total transaction of $1,375,650.00. Following the transaction, the director now directly owns 250,633 shares in the company, valued at approximately $22,985,552.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Barry E. Greene sold 58,913 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $89.99, for a total value of $5,301,580.87. Following the transaction, the president now owns 111,851 shares in the company, valued at $10,065,471.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,773 shares of company stock valued at $18,988,930. Company insiders own 3.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ALNY. Amundi Pioneer Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 12.6% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 149,659 shares of the biopharmaceutical company’s stock worth $13,986,000 after purchasing an additional 16,733 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Alnylam Pharmaceuticals by 166.3% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 6,110 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 3,816 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $470,000. Steward Partners Investment Advisory LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $83,000. Finally, Creative Planning acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $1,538,000. Institutional investors own 95.79% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: How big is the FinTech market?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit